Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 5/20 | 0.42 |
| ▸ | F9 | P00740 | 3/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828832 | 0.94 | SLC9A1 (0.67) | SLC9A1 | |
| SCHEMBL31117978 | 0.82 | SLC9A1 (0.72) | SLC9A1PLAUF9F10DYRK1A | |
| SCHEMBL829372 | 0.77 | SLC9A1 (0.50) | SLC9A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL825790 | 0.76 | SLC9A1 (1.00) | SLC9A1 | |
| SCHEMBL2335640 | 0.76 | SLC9A1 (0.54) | SLC9A1PLAUF9F10 | |
| SCHEMBL828939 | 0.76 | SLC9A1 (0.65) | SLC9A1PLAU | |
| SCHEMBL828437 | 0.76 | SLC9A1 (0.65) | SLC9A1L3MBTL1 | |
| SCHEMBL828380 | 0.76 | SLC9A1 (0.49) | SLC9A1PLAU | |
| SCHEMBL829531 | 0.76 | SLC9A1 (0.60) | SLC9A1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3505060 | 0.76 | SLC9A1 (0.53) | SLC9A1PLAUF9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4536354-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240009101-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20230404886-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023239972-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11766392-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11628132-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220296486-A1 | Minoxidil Adjuvant Therapies | Jupiter Wellness, Inc. | 2022-09-22 | — | — | US | disclosed |
| US-8793078-B2 | Method for predicting activation energy using atomic fingerprint descriptor or atomic descriptor | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2014-07-29 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2633884-A1 | Obesity small molecules | Akron Molecules GmbH (AT) | 2013-09-04 | — | — | EP | disclosed |
| US-20130030007-A1 | Obesity Small Molecules | AKRON MOLECULES GMBH (AT) | 2013-01-31 | — | — | US | disclosed |
| US-20120084012-A1 | METHOD FOR PREDICTING ACTIVATION ENERGY USING ATOMIC FINGERPRINT DESCRIPTOR OR ATOMIC DESCRIPTOR | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2012-04-05 | — | — | US | disclosed |
| US-20110213558-A1 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2011-09-01 | — | — | US | disclosed |
| EP-2354987-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | Bioinformatics&Molecular Design Research Center (KR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011083150-A2 | OBESITY SMALL MOLECULES | AKRON MOLECULES GMBH (AT) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010056053-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | 사단법인 분자설계연구소 (KR) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | SLC9A1 236/4885HDAC3 2103/4885HDAC4 1267/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | SLC9A1 2001/4885HDAC3 619/4885HDAC4 992/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | SLC9A1 357/4885HDAC3 2114/4885HDAC4 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.